Different profiles of carcinogen exposure in Chinese compared with US cigarette smokers

Tobacco Control

Volumn 24, Issue e4, 2015, Pages e258-e263

  Benowitz, Neal L ^a,b   Gan, Quan ^c   Goniewicz, Maciej L ^d   Lu, Wei ^c   Xu, Jiying ^c   Li, Xinjian ^c   Jacob, Peyton ^a,b   Glantz, Stanton ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Shanghai Center for Disease Control and Prevention   (China)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4-(N-METHYL-N-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; BIOLOGICAL MARKER; CARCINOGEN; NITROSAMINE; PYRENE; PYRENE DERIVATIVE;

ADULT; ADVERSE EFFECTS; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; PRODUCT SAFETY; SMOKING; UNITED STATES; URINE;

ADULT; BIOMARKERS; CARCINOGENS; CHINA; CONSUMER PRODUCT SAFETY; FEMALE; HUMANS; MALE; NITROSAMINES; PYRENES; SMOKING; UNITED STATES;

EID: 84949812436     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tobaccocontrol-2014-051945     Document Type: Article

References (44)

1. Gu D, Kelly TN, Wu X, et al. Mortality attributable to smoking in China. N Engl J Med 2009;360:150-9.
2. Zhang J, Ou JX, Bai CX. Tobacco smoking in China: prevalence, disease burden, challenges and future strategies. Respirology 2011;16:1165-72.
3. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013;368:351-64.
4. Fujieda M, Yamazaki H, Saito T, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004;25:2451-8.
5. Liu T, Xie CB, Ma WJ, et al. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies. Environ Mol Mutagen 2013;54:133-40.
6. Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer 2012;131:2724-32.
7. Yuan JM, Butler LM, Stepanov I, et al. Urinary tobacco smoke-constituent biomarkers for assessing risk of lung cancer. Cancer Res 2014;74:401-11.
8. Church TR, Anderson KE, Caporaso NE, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev 2009;18:260-6.
9. Hecht SS, Murphy SE, Stepanov I, et al. Tobacco smoke biomarkers and cancer risk among male smokers in the Shanghai Cohort Study. Cancer Lett 2013;334:34-8.
10. Yuan JM, Gao YT, Murphy SE, et al. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res 2011;71:6749-57.
11. Ashley DL, Beeson MD, Johnson DR, et al. Tobacco-specific nitrosamines in tobacco from U.S. brand and non-US. brand cigarettes. Nicotine Tob Res 2003;5:323-31.
12. Wu W, Zhang L, Jain RB, et al. Determination of carcinogenic tobacco-specific nitrosamines in mainstream smoke from U.S.-brand and non-U.S.-brand cigarettes from 14 countries. Nicotine Tob Res 2005;7:443-51.
13. Gray N, Zaridze D, Robertson C, et al. Variation within global cigarette brands in tar, nicotine, and certain nitrosamines: analytic study. Tob Control 2000;9:351.
14. Fischer S, Spiegelhalder B, Preussmann R. Preformed tobacco-specific nitrosamines in tobacco-role of nitrate and influence of tobacco type. Carcinogenesis 1989;10:1511-17.
15. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 1997;50:307-64.
16. Adams JD, Lee SJ, Hoffmann D. Carcinogenic agents in cigarette smoke and the influence of nitrate on their formation. Carcinogenesis 1984;5:221-3.
17. Gan Q, Lu W, Xu J, et al. Chinese 'low-tar' cigarettes do not deliver lower levels of nicotine and carcinogens. Tob Control 2010;19:374-9.
18. Benowitz NL, Dains KM, Dempsey D, et al. Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. Nicotine Tob Res 2011;13:772-83.
19. Benowitz NL, Dains KM, Hall SM, et al. Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev 2012;21:761-9.
20. Dempsey D, Tutka P, Jacob P III, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004;76:64-72.
21. Jacob P III, Havel C, Lee DH, et al. Subpicogram per milliliter determination of the tobacco-specific carcinogen metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in human urine using liquid chromatography-tandem mass spectrometry. Anal Chem 2008;80:8115-21.
22. Jacob P III, Wilson M, Benowitz NL. Determination of Phenolic Metabolites of Polycyclic Aromatic Hydrocarbons in Human Urine as Their Pentafluorobenzyl Ether Derivatives Using Liquid Chromatography-Tandem Mass Spectrometry. Anal Chem 2007;79:587-98.
23. Benowitz NL, Jacob P III, Fong I, et al. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268:296-303.
24. Feng S, Kapur S, Sarkar M, et al. Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. Toxicol Lett 2007;173:101-6.
25. Benowitz NL, Dains KM, Dempsey D, et al. Estimation of nicotine dose after lowlevel exposure using plasma and urine nicotine metabolites. Cancer Epidemiol Biomarkers Prev 2010;19:1160-6.
26. Benowitz NL, Hukkanen J, Jacob P III. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009:29-60.
27. Xia Y, Bernert JT, Jain RB, et al. Tobacco-specific nitrosamine 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanol (NNAL) in smokers in the United States: NHANES 2007-2008. Biomarkers 2011;16:112-19.
28. Yuan JM, Butler LM, Gao YT, et al. Urinary metabolites of a polycyclic aromatic hydrocarbon and volatile organic compounds in relation to lung cancer development in lifelong never smokers in the Shanghai Cohort Study. Carcinogenesis 2014;35:339-45.
29. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-44.
30. Gray N, Boyle P. The case of the disappearing nitrosamines: a potentially global phenomenon. Tob Control 2004;13:13-16.
31. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004;83:1-1438.
32. Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000;92:803-11.
33. HHS. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. Atlanta, GA: US. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010.
34. Akpan V, Huang S, Lodovici M, et al. High levels of carcinogenic polycyclic aromatic hydrocarbons (PAH) in 20 brands of Chinese cigarettes. J Appl Toxicol 2006;26: 480-3.
35. Jacob P III, Abu Raddaha AH, Dempsey D, et al. Comparison of nicotine and carcinogen exposure with water pipe and cigarette smoking. Cancer Epidemiol Biomarkers Prev 2013;22:765-72.
36. Ding YS, Zhang L, Jain RB, et al. Levels of tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons in mainstream smoke from different tobacco varieties. Cancer Epidemiol Biomarkers Prev 2008;17:3366-71.
37. Benowitz NL. Compensatory smoking of low-yield cigarettes. Risks associated with smoking cigarettes with low machine yields of tar and nicotine Smoking and Tobacco Control Monograph No 13. National Cancer Institute, 2001;13:39-63.
38. Burns DM, Dybing E, Gray N, et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob Control 2008;17:132-41.
39. Wu MT, Simpson CD, Christiani DC, et al. Relationship of exposure to coke-oven emissions and urinary metabolites of benzo(a)pyrene and pyrene in coke-oven workers. Cancer Epidemiol Biomarkers Prev 2002;11:311-14.
40. Bernert JT, Pirkle JL, Xia Y, et al. Urine concentrations of a tobacco-specific nitrosamine carcinogen in the US. population from secondhand smoke exposure. Cancer Epidemiol Biomarkers Prev 2010;19:2969-77.
41. Suwan-ampai P, Navas-Acien A, Strickland PT, et al. Involuntary tobacco smoke exposure and urinary levels of polycyclic aromatic hydrocarbons in the United States, 1999 to 2002. Cancer Epidemiol Biomarkers Prev 2009;18:884-93.
42. Yuan JM, Gao YT, Wang R, et al. Urinary levels of volatile organic carcinogen and toxicant biomarkers in relation to lung cancer development in smokers. Carcinogenesis 2012;33:804-9.
43. HHS. The health consequences of smoking-50 years of progress. A report of the surgeon general. Atlanta, GA: US. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
44. Alshaarawy O, Zhu M, Ducatman A, et al. Polycyclic aromatic hydrocarbon biomarkers and serum markers of inflammation. A positive association that is more evident in men. Environ Res 2013;126:98-104.